<?xml version="1.0" encoding="UTF-8"?>
<TED_EXPORT xmlns:xlink="http://www.w3.org/1999/xlink"
            xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
            xmlns="ted/R2.0.9.S02/publication"
            xmlns:n2016="ted/2016/nuts"
            xsi:schemaLocation="ted/R2.0.9.S02/publication TED_EXPORT.xsd"
            VERSION="R2.0.9.S02.E01"
            DOC_ID="060408-2018"
            EDITION="2018028">
   <TECHNICAL_SECTION>
      <RECEPTION_ID>18-061444-001</RECEPTION_ID>
      <DELETION_DATE>20180312</DELETION_DATE>
      <FORM_LG_LIST>EN </FORM_LG_LIST>
      <COMMENTS>From Convertor</COMMENTS>
   </TECHNICAL_SECTION>
   <LINKS_SECTION>
      <XML_SCHEMA_DEFINITION_LINK xlink:type="simple"
                                  xlink:href="http://ted.europa.eu"
                                  xlink:title="TED WEBSITE"/>
      <OFFICIAL_FORMS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
      <FORMS_LABELS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
      <ORIGINAL_CPV_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
      <ORIGINAL_NUTS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
   </LINKS_SECTION>
   <CODED_DATA_SECTION>
      <REF_OJS>
         <COLL_OJ>S</COLL_OJ>
         <NO_OJ>28</NO_OJ>
         <DATE_PUB>20180209</DATE_PUB>
      </REF_OJS>
      <NOTICE_DATA>
         <NO_DOC_OJS>2018/S 028-060408</NO_DOC_OJS>
         <URI_LIST>
            <URI_DOC LG="EN">http://ted.europa.eu/udl?uri=TED:NOTICE:060408-2018:TEXT:EN:HTML</URI_DOC>
         </URI_LIST>
         <LG_ORIG>EN</LG_ORIG>
         <ISO_COUNTRY VALUE="UK"/>
         <IA_URL_GENERAL>http://www.nhsscotlandprocurement.scot.nhs.uk/</IA_URL_GENERAL>
         <IA_URL_ETENDERING>https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html</IA_URL_ETENDERING>
         <ORIGINAL_CPV CODE="33600000">Pharmaceutical products</ORIGINAL_CPV>
         <n2016:PERFORMANCE_NUTS CODE="UKM">SCOTLAND</n2016:PERFORMANCE_NUTS>
         <n2016:CA_CE_NUTS CODE="UKM">SCOTLAND</n2016:CA_CE_NUTS>
         <VALUES>
            <VALUE TYPE="ESTIMATED_TOTAL" CURRENCY="GBP">2244011</VALUE>
         </VALUES>
      </NOTICE_DATA>
      <CODIF_DATA>
         <DS_DATE_DISPATCH>20180207</DS_DATE_DISPATCH>
         <DT_DATE_FOR_SUBMISSION>20180312 12:00</DT_DATE_FOR_SUBMISSION>
         <AA_AUTHORITY_TYPE CODE="6">Body governed by public law</AA_AUTHORITY_TYPE>
         <TD_DOCUMENT_TYPE CODE="3">Contract notice</TD_DOCUMENT_TYPE>
         <NC_CONTRACT_NATURE CODE="2">Supplies</NC_CONTRACT_NATURE>
         <PR_PROC CODE="1">Open procedure</PR_PROC>
         <RP_REGULATION CODE="5">European Union, with participation by GPA countries</RP_REGULATION>
         <TY_TYPE_BID CODE="1">Submission for all lots</TY_TYPE_BID>
         <AC_AWARD_CRIT CODE="2">The most economic tender</AC_AWARD_CRIT>
         <MA_MAIN_ACTIVITIES CODE="H">Health</MA_MAIN_ACTIVITIES>
         <HEADING>01B02</HEADING>
         <INITIATOR>01</INITIATOR>
         <DIRECTIVE VALUE="2014/24/EU"/>
      </CODIF_DATA>
   </CODED_DATA_SECTION>
   <TRANSLATION_SECTION>
      <ML_TITLES>
         <ML_TI_DOC LG="BG">
            <TI_CY>Обединено кралство</TI_CY>
            <TI_TOWN>Единбург</TI_TOWN>
            <TI_TEXT>
               <P>Фармацевтични продукти</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="CS">
            <TI_CY>Spojené království/Velká Británie</TI_CY>
            <TI_TOWN>Edinburgh</TI_TOWN>
            <TI_TEXT>
               <P>Léčivé přípravky a zdravotnické prostředky</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="DA">
            <TI_CY>Forenede Kongerige, Det</TI_CY>
            <TI_TOWN>Edinburgh</TI_TOWN>
            <TI_TEXT>
               <P>Lægemidler</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="DE">
            <TI_CY>das Vereinigte Königreich</TI_CY>
            <TI_TOWN>Edinburgh</TI_TOWN>
            <TI_TEXT>
               <P>Arzneimittel</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="EL">
            <TI_CY>Ηνωμένο Βασίλειο</TI_CY>
            <TI_TOWN>Εδιμβούργο</TI_TOWN>
            <TI_TEXT>
               <P>Φαρμακευτικά προϊόντα</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="EN">
            <TI_CY>United Kingdom</TI_CY>
            <TI_TOWN>Edinburgh</TI_TOWN>
            <TI_TEXT>
               <P>Pharmaceutical products</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="ES">
            <TI_CY>Reino Unido</TI_CY>
            <TI_TOWN>Edimburgo</TI_TOWN>
            <TI_TEXT>
               <P>Productos farmacéuticos</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="ET">
            <TI_CY>Suurbritannia / Ühendkuningriik</TI_CY>
            <TI_TOWN>Edinburgh</TI_TOWN>
            <TI_TEXT>
               <P>Ravimid</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="FI">
            <TI_CY>Yhdistynyt kuningaskunta</TI_CY>
            <TI_TOWN>Edinburgh</TI_TOWN>
            <TI_TEXT>
               <P>Farmaseuttiset tuotteet</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="FR">
            <TI_CY>Royaume-Uni</TI_CY>
            <TI_TOWN>Édimbourg</TI_TOWN>
            <TI_TEXT>
               <P>Produits pharmaceutiques</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="GA">
            <TI_CY>Ríocht Aontaithe, an</TI_CY>
            <TI_TOWN>Dún Éideann</TI_TOWN>
            <TI_TEXT>
               <P>Pharmaceutical products</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="HR">
            <TI_CY>Ujedinjena Kraljevina</TI_CY>
            <TI_TOWN>Edinburgh</TI_TOWN>
            <TI_TEXT>
               <P>Farmaceutski proizvodi</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="HU">
            <TI_CY>Egyesült Királyság</TI_CY>
            <TI_TOWN>Edinburgh</TI_TOWN>
            <TI_TEXT>
               <P>Gyógyszerészeti termékek</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="IT">
            <TI_CY>Regno Unito</TI_CY>
            <TI_TOWN>Edimburgo</TI_TOWN>
            <TI_TEXT>
               <P>Prodotti farmaceutici</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="LT">
            <TI_CY>Jungtinė Karalystė, Didžioji Britanija</TI_CY>
            <TI_TOWN>Edinburgas</TI_TOWN>
            <TI_TEXT>
               <P>Farmacijos produktai</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="LV">
            <TI_CY>Apvienotā Karaliste</TI_CY>
            <TI_TOWN>Edinburga</TI_TOWN>
            <TI_TEXT>
               <P>Farmācijas izstrādājumi</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="MT">
            <TI_CY>Ir-Renju Unit</TI_CY>
            <TI_TOWN>Edinbugh</TI_TOWN>
            <TI_TEXT>
               <P>Prodotti farmaċewtiċi</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="NL">
            <TI_CY>Verenigd Koninkrijk</TI_CY>
            <TI_TOWN>Edinburgh</TI_TOWN>
            <TI_TEXT>
               <P>Farmaceutische producten</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="PL">
            <TI_CY>Zjednoczone Królestwo</TI_CY>
            <TI_TOWN>Edynburg</TI_TOWN>
            <TI_TEXT>
               <P>Produkty farmaceutyczne</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="PT">
            <TI_CY>Reino Unido</TI_CY>
            <TI_TOWN>Edimburgo</TI_TOWN>
            <TI_TEXT>
               <P>Produtos farmacêuticos</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="RO">
            <TI_CY>Regatul Unit</TI_CY>
            <TI_TOWN>Edinburgh</TI_TOWN>
            <TI_TEXT>
               <P>Produse farmaceutice</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="SK">
            <TI_CY>Spojené kráľovstvo</TI_CY>
            <TI_TOWN>Edinburgh</TI_TOWN>
            <TI_TEXT>
               <P>Farmaceutické výrobky</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="SL">
            <TI_CY>Združeno kraljestvo</TI_CY>
            <TI_TOWN>Edinburgh</TI_TOWN>
            <TI_TEXT>
               <P>Farmacevtski proizvodi</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="SV">
            <TI_CY>Förenade kungariket</TI_CY>
            <TI_TOWN>Edinburgh</TI_TOWN>
            <TI_TEXT>
               <P>Läkemedel</P>
            </TI_TEXT>
         </ML_TI_DOC>
      </ML_TITLES>
      <ML_AA_NAMES>
         <AA_NAME LG="EN">The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority")</AA_NAME>
      </ML_AA_NAMES>
   </TRANSLATION_SECTION>
   <FORM_SECTION>
      <NOTICE_UUID>c1289233-5fd9-4a33-b8e1-67768307ccb5</NOTICE_UUID>
      <F02_2014 CATEGORY="ORIGINAL" FORM="F02" LG="EN">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority")</OFFICIALNAME>
               <ADDRESS>Gyle Square (NSS Head Office), 1 South Gyle Crescent</ADDRESS>
               <TOWN>Edinburgh</TOWN>
               <POSTAL_CODE>EH12 9EB</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <CONTACT_POINT>Hazel Johnstone</CONTACT_POINT>
               <PHONE>+44 1698794561</PHONE>
               <E_MAIL>hazel.johnstone@nhs.net</E_MAIL>
               <n2016:NUTS CODE="UKM"/>
               <URL_GENERAL>http://www.nhsscotlandprocurement.scot.nhs.uk/</URL_GENERAL>
               <URL_BUYER>http://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA11883</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CENTRAL_PURCHASING/>
            <DOCUMENT_FULL/>
            <URL_DOCUMENT>https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html</URL_DOCUMENT>
            <ADDRESS_FURTHER_INFO_IDEM/>
            <URL_PARTICIPATION>https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html</URL_PARTICIPATION>
            <CA_TYPE VALUE="BODY_PUBLIC"/>
            <CA_ACTIVITY VALUE="HEALTH"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Anagrelide, Ezetimibe, Ivabradine &amp; Rosuvastatin</P>
            </TITLE>
            <REFERENCE_NUMBER>NP47518</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="33600000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SUPPLIES"/>
            <SHORT_DESCR>
               <P>This framework is for the supply of Anagrelide, Ezetimibe, Ivabradine &amp; Rosuvastatin tablets to health boards across NHS Scotland.</P>
               <P>The Authority intends awarding a single-supplier framework agreement on a line by line basis. Full details can be found within the ITT.</P>
            </SHORT_DESCR>
            <VAL_ESTIMATED_TOTAL CURRENCY="GBP">2244011</VAL_ESTIMATED_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="UKM"/>
               <MAIN_SITE>
                  <P>All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>This framework is for the supply of Anagrelide, Ezetimibe, Ivabradine &amp; Rosuvastatin tablets to health boards across NHS Scotland.</P>
                  <P>The Authority intends awarding a single-supplier framework agreement on a line by line basis. Full details can be found within the ITT.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Logistics</AC_CRITERION>
                  <AC_WEIGHTING>5</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>95</AC_WEIGHTING>
               </AC_PRICE>
               <VAL_OBJECT CURRENCY="GBP">2244011</VAL_OBJECT>
               <DURATION TYPE="MONTH">15</DURATION>
               <RENEWAL/>
               <RENEWAL_DESCR>
                  <P>Option to extend by a further two (2) periods of up to twelve (12) months each, upon giving not less than three (3) months written notice such notice to expire no later than the date the framework agreement is due to expire.</P>
               </RENEWAL_DESCR>
               <NO_ACCEPTED_VARIANTS/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <LEFTI>
            <SUITABILITY>
               <P>Economic operators may be excluded from this competition if they are in breach of any of the situation referred to in regulation 58 of the Public Contracts (Scotland) Regulations 2015.</P>
            </SUITABILITY>
            <TECHNICAL_PROFESSIONAL_INFO>
               <P>1) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by approved by the MHRA for all tendered Medicines at the date of submission of the tender;</P>
               <P>2) Potential Framework Participants and any sub-contractors must possess a valid certification of BS EN ISO 9001 or equivalent;</P>
               <P>3) All tendered Goods must comply with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labeling on pack design.</P>
            </TECHNICAL_PROFESSIONAL_INFO>
            <TECHNICAL_PROFESSIONAL_MIN_LEVEL>
               <P>1) Confirmation of the existence of a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender should be included in the Qualification Envelope of the ITT under the Technical and Professional ability: Quality Control;</P>
               <P>2) Confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent. Confirmation of such certification should be included in the Qualification Envelope of the ITT under Technical and Professional ability: Quality Assurance Schemes;</P>
               <P>3) Confirmation that samples for tendered Goods will be supplied upon request to ensure compliance with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labeling on pack design. Confirmation of sample provision should be provided in the Qualification Envelope of the ITT under Technical and Professional ability: Products.</P>
            </TECHNICAL_PROFESSIONAL_MIN_LEVEL>
         </LEFTI>
         <PROCEDURE>
            <PT_OPEN/>
            <FRAMEWORK>
               <SEVERAL_OPERATORS/>
            </FRAMEWORK>
            <CONTRACT_COVERED_GPA/>
            <DATE_RECEIPT_TENDERS>2018-03-12</DATE_RECEIPT_TENDERS>
            <TIME_RECEIPT_TENDERS>12:00</TIME_RECEIPT_TENDERS>
            <LANGUAGES>
               <LANGUAGE VALUE="EN"/>
            </LANGUAGES>
            <DURATION_TENDER_VALID TYPE="MONTH">3</DURATION_TENDER_VALID>
            <OPENING_CONDITION>
               <DATE_OPENING_TENDERS>2018-03-12</DATE_OPENING_TENDERS>
               <TIME_OPENING_TENDERS>12:00</TIME_OPENING_TENDERS>
            </OPENING_CONDITION>
         </PROCEDURE>
         <COMPLEMENTARY_INFO>
            <NO_RECURRENT_PROCUREMENT/>
            <EORDERING/>
            <EINVOICING/>
            <EPAYMENT/>
            <INFO_ADD>
               <P>The estimated value referred to in Section II.I.5 and II.2.6 covers the initial fifteen (15) months contract duration and the two (2) x twelve (12) month extension periods of the framework agreement.</P>
               <P>The buyer is using PCS-Tender to conduct this ITT exercise. The Project code is 10220. For more information see:</P>
               <P>— http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343.</P>
               <P>(SC Ref:529510).</P>
            </INFO_ADD>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority")</OFFICIALNAME>
               <ADDRESS>Gyle Square (NSS Head Office), 1 South Gyle Crescent</ADDRESS>
               <TOWN>Edinburgh</TOWN>
               <POSTAL_CODE>EH12 9EB</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <PHONE>+44 1698794410</PHONE>
               <URL>http://www.nhsscotlandprocurement.scot.nhs.uk/</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>The Authority will notify economic operators who submitted a tender or (where no deselection notification has previously been made) applied to be selected to tender, of its decision to award the framework agreement which notification will contain among other information, a summary of the reasons why the economic operator was unsuccessful.</P>
               <P>The notification will incorporate a 'standstill period' of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority despatches the notices and the date on which the Authority proposes to conclude the relevant framework agreement.</P>
               <P>The bringing of court proceedings against the Authority during the standstill period will automatically continue the prohibition on entering into the framework agreement until the court proceedings are determined, discontinued or disposed of, or the court, by interim order, brings to an end the prohibition.</P>
               <P>The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderers.</P>
               <P>The bringing of court proceedings against the Authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. </P>
               <P>Otherwise, the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-02-07</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F02_2014>
   </FORM_SECTION>
</TED_EXPORT>
